Merck FDA Approval of IDVYNSO HIV Treatment Drug
Rahway, New Jersey, USA – April 21, 2026 In a major breakthrough for HIV therapeutics, Merck has received U.S....
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody NSCLC Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Rahway, New Jersey, USA – April 21, 2026 In a major breakthrough for HIV therapeutics, Merck has received U.S....
Barcelona, Spain – October 15, 2025 – Gilead Sciences, Inc. (NASDAQ: GILD) unveiled new data across its HIV prevention...
